1 / 8

Antibacterial Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2024

Prevalence of bacterial infections and diseases is especially high in third world countries and significantly hampers quality of life across the globe. Further adding to the woes of the affected population is the increasing strains of bacteria that are resistant to conventional antibacterial drugs. The epidemic of antibacterial resistance has spurred interest among the global healthcare organizations and a few pharmaceutical companies and research institutes to develop next-generation antibacterial drugs to effectively thwart such maladies. Unregulated and over prescription of antibacterial drugs has led to increased drug resistance. Moreover, genetic mutations are considered to be another major reason for antibacterial drug resistance. Ironically, these factors have greatly constrained the growth of antibacterial drugs market for years.

AlbertR
Download Presentation

Antibacterial Drugs Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2024

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. ANTIBACTERIAL DRUGS MARKET Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2016–2024 © Coherent market Insights. All Rights Reserved © Coherent market Insights. All Rights Reserved

  2. REPORT DESCRIPTION Healthcare Revenue Cycle Management Market Overview Prevalence of bacterial infections and diseases is especially high in third world countries and significantly hampers quality of life across the globe. Further adding to the woes of the affected population is the increasing strains of bacteria that are resistant to conventional antibacterial drugs. The epidemic of antibacterial resistance has spurred interest among the global healthcare organizations and a few pharmaceutical companies and research institutes to develop next-generation antibacterial drugs to effectively thwart such maladies. Unregulated and over prescription of antibacterial drugs has led to increased drug resistance. Moreover, genetic mutations are considered to be another major reason for antibacterial drug resistance. Ironically, these factors have greatly constrained the growth of antibacterial drugs market for years. Request Sample Copy of the Business Report: https://www.coherentmarketinsights.com/insight/request-sample/177 Invention of Penicillin was a major breakthrough for treating bacterial infections. This stimulated research for more antibacterial drugs to treat different bacteria such as Escherichia coli, Klebsiella pneumonia, Staphylococcus aureus (MRSA) and Enterococcus species. However, price control and decreasing financial incentives discouraged pharmaceutical companies to conduct further research in this field. This has limited treatment options for bacterial infections, while discovery of new strains of infectious bacteria is on rise. Below is the timeline of antibacterial drug discovery: © Coherent market Insights. All Rights Reserved

  3. REPORT DESCRIPTION The timeline highlights the large void in introduction of new antibacterial drugs during period 1960– 2000. Streptomycin, sulfonamide, macrolide, nalidixic acid, aminoglycoside, tetracycline, and linezolid are among the bacterial resistant drugs. Prospective drug candidates in research to improve the future outlook of the global antibacterial drugs market The global antibacterial drugs market potential is estimated based on the current antibacterial drug classes, including those mentioned above and those in clinical trials. As of March 2016, there are around 37 drugs in clinical development for treating serious bacterial infections. These drugs are intended to be primarily launched in the U.S. Moreover, FDA is encouraging development of new antibacterial drugs by laying out guidelines for the industry on the types of clinical studies to be conducted on antibacterial drug evaluation. This factor coupled with various incentives for research companies would create a positive outlook for the global antibacterial drugs resistance market in the near future. Also, in March 2017, the WHO released a list of pathogens, classified based on the criticality/urgency, for which newer antibacterial drugs are required. The different environmental forces working towards development of newer antibacterial drugs would be a major continuing factor for the global antibacterial drugs market growth. Request a Customization: https://www.coherentmarketinsights.com/insight/request-customization/177 © Coherent market Insights. All Rights Reserved

  4. REPORT DESCRIPTION Alarming rise in drug resistant strains of bacteria driving awareness initiatives and programs by global healthcare organizations to back companies in the antibacterial drugs market According to the Centers for Drug Disease Prevention and Control (CDC), every year at least 2 million people in the U.S. acquire bacterial infections that are resistant to drugs. Antibacterial resistance results in 23,000 deaths every year in the U.S. Moreover, according to the European Antimicrobial Resistance Surveillance Network (EARS-Net) data of November 2016, antibiotic resistance is higher in southern and south-easternEurope than in northern Europe. Multiple drug resistance, as in case of tuberculosis, has further aggravated the treatment for specific conditions. According to the World health Organization (WHO), India has the highest burden of TB worldwide. Furthermore, the MDR-TB cases resistant to second-line drugs was 16% among already treated cases reported in 2015. Globally, an estimated 480,000 people developed MDR-TB in 2015 (WHO). The Government of India has drafted a national Strategic Plan 2017-2025 for eradicating TB in India. This would further propel the antibacterial drugs market in India. Get Exclusive Discount on this CMI Report: https://www.coherentmarketinsights.com/insight/request-discount/177 Some of the major players in the global antibacterial drugs market are Pfizer, Inc., Johnson & Johnson, AstraZeneca plc, F. Hoffmann-La Roche AG, Merck & Co., Inc., Evotec Pharmaceuticals, Allecra Therapeutics, Kyorin Pharmaceutical, and Allergan plc. © Coherent market Insights. All Rights Reserved

  5. ABOUT COHERENT MARKET INSIGHTS ABOUT US Coherent Market Insights is a global market intelligence and consulting organization focused on assisting its plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, with an office at the global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods. We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele. SERVICES CUSTOMIZED RESEARCH INDUSTRY ANALYSIS SYNDICATED RESEARCH COUNTRY SPECIFIC STUDIES MARKET INTELLIGENCE SERVICES CONSULT STUDIES © Coherent market Insights. All Rights Reserved

  6. ABOUT CMI SECTOR COVERAGE BIOTECHNOLOGY CLINICAL DIAGNOSTIC HEALTHCARE IT MEDICAL DEVICES MEDICAL IMAGING PHARMACEUTICAL OUR CLIENTS  Global Leading Equipment and System Manufacturers  Marketing Consultancies and the Advertising Industry  Component Providers and System Integrators  Private and Government organization  Distributors, Retailors and Value Added Resellers  Outsourcing Companies  Healthcare IT Solutions Developers  Universities and Business Schools. © Coherent market Insights. All Rights Reserved

  7. KEY STATS RESEARCH SOLUTIONS 100+ GLOBAL REPORTS FEASIBILITY STUDIES Insights Published Per Year CUSTOMIZED SOLUTIONS 150+ COUNTRY ANALYSIS Consulting Projects Till Date CONSULT PROJECTS SURVEY RESEARCH 125+ EXCEL FORECAST DATABASE Clients Worldwide Per Year COMPETITIVE ASSESSMENT TECHNOLOGY SNIPPETS 110+ Analysts and Contract Consultants Coherent Market Insights excels at offering unmatched actionable market intelligence across various industry verticals, including chemicals, healthcare, and food & beverages, to name a few. We implement holistic market research methodology in order to result in the best possible market research reports across various industries worldwide. Based on our unmatched expertise across various industries—no matter how large or small, how complex or unique—we help our clients achieve better outcomes with uniquely designed and highly customized solutions. Our coverage includes insights that help our clients ensure sustained growth in developed markets and also key inputs to help them tap into emerging markets and exploit the plethora of opportunities posed therein. © Coherent market Insights. All Rights Reserved

  8. THANK YOU To know more about us, visit our website: www.coherentmarketinsights.com For sales queries or new topics email us on: sales@coherentmarketinsights.com For other queries contact: Mr. Shah (Manager - Business Development) Coherent Market Insights sales@coherentmarketinsights.com +1-206-701-6702 © Coherent market Insights. All Rights Reserved

More Related